SEATTLE, March 2 /PRNewswire-FirstCall/ -- Pacific Biomarkers, Inc. ("PBI"), a leading provider of specialized biomarker and contract research services, today announced that Ron Helm, Chief Executive Officer, will present at the ROTH Capital Partners 22nd Annual OC Growth Stock Conference. The conference will be held at the Ritz Carlton in Dana Point, California March 15-17, 2010.
The three-day institutional investor conference will feature management presentations from over 350 small-cap public companies. The broad spectrum of presenting companies will represent the following sectors: Healthcare, Media & Internet, Enterprise Software, Gaming, Semiconductors, Global Energy and Industrials, and Retail & Consumer.
For more information about this invitation-only event, please visit the conference website at www.roth.com or contact your ROTH representative at 800-933-6830.
ROTH Capital Partners is a full-service investment banking firm dedicated to the small-cap public market. Since its inception in 1984, ROTH has been an innovator in this space. ROTH has participated in underwriting IPOs for small-cap companies, has helped develop the PIPE financing structure, and has more recently become active in underwriting offerings from shelf registration statements. ROTH was one of the first U.S. investment banks to focus on financing small-cap Chinese companies and established a Representative Office in Shanghai in 2007.
About Pacific Biomarkers, Inc. (PBI)
Established in 1989, PBI provides specialized central laboratory and contract research services to support pharmaceutical and diagnostic manufacturers conducting human clinical trial research. The Company provides expert services in the areas of cardiovascular disease, diabetes, osteoporosis, arthritis, and nutrition. The PBI laboratory is accredited by the College of American Pathologists, New York State, and the Lipid Standardization Program. PBI's clients include many of the world's largest pharmaceutical, biotech, and diagnostic companies. PBI also provides clinical biomarker services focusing on the emerging field of biomarker assay development and testing. Services include validating and performing ligand-binding assays for novel clinical biomarkers, immunogenicity testing, cell based assay testing and multiplex testing.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
CONTACT: Ron Helm, CEO of Pacific Biomarkers, Inc., +1-206-298-0068, or RJ
Falkner & Company, Inc., Investor Relations Counsel, 1-800-377-9893,
info@rjfalkner.com
Web site: http://www.pacbio.com/
http://www.roth.com/
